SCHEDULE 13D/A: Hatteras Venture Funds Divest Clearside Biomedical Shares, Individuals Maintain Small Stakes

Hatteras Venture entities have updated their Schedule 13D filing for Clearside Biomedical, Inc., reporting zero beneficial ownership for the funds while associated individuals retain minor holdings.

Summary

• This document is Amendment No. 7 to the Schedule 13D filing for Clearside Biomedical, Inc. (Issuer), regarding its Common Stock, $0.001 Par Value.
• The filing updates beneficial ownership information for several Hatteras Venture entities and associated individuals.
• Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Partners IV SBIC, LP, Hatteras Venture Advisors IV, LLC, Hatteras Venture Partners IV, LP, and Hatteras NC Fund, LP now report 0 shares and 0% beneficial ownership of Clearside Biomedical, Inc. common stock.
• Individual reporting persons maintain beneficial ownership: John C. Crumpler holds 125,793 shares (0.2%), Robert A. Ingram holds 130,881 shares (0.2%), Kenneth B. Lee holds 86,324 shares (0.1%), Clay B. Thorp holds 313,641 shares (0.4%), and Douglas Reed holds 127,011 shares (0.2%).
• Clay B. Thorp's reported ownership includes 152,500 shares subject to options exercisable within 60 days of February 21, 2025.
• The event requiring this filing occurred on September 13, 2024.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of ownership changes without commentary on company performance or strategy.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Primarily impacts shareholders by providing updated transparency on significant beneficial ownership stakes, particularly the divestment by Hatteras Venture funds.

Key Dates

Keywords

SEC filing, Schedule 13D, beneficial ownership, Clearside Biomedical, Hatteras Venture, institutional ownership, insider ownership, common stock, biopharmaceutical